www.actinogen.com.au 1

UNDERSTANDING ALZHEIMER’SThe Brains Behind Saving Yours

ACTINOGEN MEDICAL LIMITEDLEVEL 9, SUITE 1, 68 PITT STREET, SYDNEY, NSW 2000 AUSTRALIA

2

Program Contents

Order of Events

Special Thanks

5:30pm

6:00pm

6:10pm

6:20pm

6:30pm

6:40pm

6:50pm

7:10pm

Guest Registration

Erin Ramsay – Welcome and Introduction

Prof. Ralph Martins – Early Detection and Prevention of Alzheimer’s Disease

Prof. Colin Masters – The Natural History of Alzheimer’s Disease

Dr. Bill Ketelbey – Translating Research into Medicines

Anne Fairhall – Carer Experience with Dementia

Panel Q&A Session w/ live twitter feed

Announcements and Networking

Order of Events

Special Thanks

About Alzheimer’s Disease

Speaker Biographies

Speaker Associated Links & News

Actinogen Medical Highlights

2

2

3

5

7

8

www.actinogen.com.au 3

About Alzheimer’s Disease

Alzheimer’s disease (AD) is emerging as one of the most important global public health issues to face modern humanity. It is the most common cause of dementia, accounting for over 70% of cases, and is characterised by cognitive decline, abnormal β-amyloid protein plaque deposition in the brain and neurotoxicity with loss of the brain tissue. The incidence increases significantly with age, with 1 in 3 over the age of 85 suffering from the disease. With the aging population and success of medical interventions in many other disease areas, the prevalence of AD is rapidly increasing. Data from the 2015 World Alzheimer’s Report estimates there are 47 million people globally affected by AD, with the number set to double every 20 years. The burden of the disease is global, with nearly 70% of the increase expected to be in middle and low income countries.

In Australia, more than 342,800 people are living with dementia, with the number expected to be almost 900,000 by 2050. The number of people with AD in the United

Kingdom (UK) has increased since the late 1990s and is a major cause of morbidity and mortality. Of the 5.3 million Americans with AD, an estimated 5.1 million are aged 65 years and older, and approximately 200,000 are under the age of 65. By 2025, the number of people aged 65 and older with AD is estimated to reach 7.1 million – a 40% increase from the 5.1 million aged 65 and older affected in 2015. By 2050, this number could triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease.

Alzheimer’s disease is emerging as the most significant health challenge of our time

4

The cost of treating AD is approaching one trillion dollars – if dementia care was a country it would be the 18thlargest economy. AD is one of the leading causes of death in the developed world, and in Australia is second only to ischemic heart disease. Compounding this societal burden however, is the relatively limited benefit provided by the currently available treatment options for Alzheimer’s disease. None of the main four registered drugs (donepezil, rivastigmine, galantamine and memantine, which are available in a number of different formulations), provide much more than short-term symptomatic benefit, and significantly, none are disease modifying.The Alzheimer’s disease community desperately needs new alternative treatment options, and ideally, drugs with a disease modifying potential.

Alzheimer’s disease is now understood to be a disease that develops years before it becomes symptomatic, with the development of dementia. It is likely that brain pathology begins to develop up to 15 years before the appearance of mild cognitive impairment or clinical dementia. The discovery and development of mechanisms for earlier diagnosis and treatment is therefore vital to be able to significantly impact the burden of the disease on modern society.

While no single clear cause for the development of Alzheimer’s disease has been reported, there is strong evidence to support an association between excess cortisol – the “stress hormone”, and the development of Alzheimer’s disease. Excess cortisol has been shown to cause cognitive decline, and to lead to β-amyloid plaque deposition and neurotoxicity in the brain, and to the loss of brain tissue. All these are hallmarks of Alzheimer’s disease.

www.actinogen.com.au 5

Contact Details

Speaker Biographies

PROFESSOR COLIN L. MASTERSB Med Sci (Hons), MBBS, MD, Hon.DLitt W.Aust., FRCPath, FRCPA, FAA, FTSE

• Laureate Professor of Dementia Research• Head, Neurodegeneration Division• The Florey Institute • The University of Melbourne

PROFESSOR RALPH MARTINS AOB. Sc. (Hons), PhD. KSJ, CitWA, MAICD

• Inaugural Chair – Alzheimer’s and Ageing• Edith Cowan University• Director, Centre of Excellence for Alzheimer’s

Disease Research and Care• Director of Research, McCusker Alzheimer’s Research Foundation

The Florey Institute of Neuroscience and Mental Health 30 Royal Parade, Parkville, VIC 3010 Australia

Colin Masters has focused his career on research in Alzheimer’s disease and other neurodegenerative diseases, including Creutzfeldt-Jakob

disease. His work over the last 35 years is widely acknowledged as having had a major influence on Alzheimer’s disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the Aβ amyloid protein which causes Alzheimer’s disease. This work has led to the continued development of diagnostics and therapeutic strategies. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary preparatory step for therapeutic disease modification. Professor Masters is currently the Head of the Neurodegeneration Division, Florey Institute and a Laureate Professor at the University of Melbourne. He is also a consultant at the Royal Melbourne Hospital. His achievements have been recognised by the receipt of many international awards.

T: +613 9035 6575F: +61 3 9035 8768

E: c.masters@unimelb.edu.au

Sir James McCusker Alzheimer’s Disease Research UnitSuite 22, Hollywood Medical Centre85 Monash Avenue, Nedlands, WA 6009 Australia

Contact Details

T: +61 8 9347 4200F: +61 8 9347 4299 M650

E: r.martins@ecu.edu.au

Ralph Martins is a leading expert in Alzheimer’s disease, whose career spanning 30+ years, has resulted in 350+ publications in mid to high impact journals. He has established a research unit currently comprising 60+ research staff and postgraduate students, who are working to understand the cause(s) of AD. His research has led to the identification of 3 novel drug candidates, attracting Federal funding and the interest of key commercial partners. He established the McCusker Foundation for Alzheimer’s Disease Research in 2000 and in 2004 was appointed to the inaugural Chair in Ageing & Alzheimer’s at Edith Cowan University. He is the winner of a number of awards, including 2010 WA Australian of the Year, 2011 WA Citizen of the Year and was awarded an Australia Day honour Officer of the Order of Australia (OA) 2013. He holds board memberships of 3 research foundations, several committees for national research organisations. His research is world renowned and is considered an international expert in his field. In 2016 he was appointed to a part time position as Professor in Biomedical Sciences, at Macquarie University, NSW concurrently with his Edith Cowan University appointment. He also has adjunct appointments with the University of Western Australia in the School of Psychiatry and Clinical Neurosciences, Curtin University of Technology in the School of Biomedical Sciences and Hokkaido University, Japan.

6

Contact Details

DR. BILL KETELBEYMBBCh, FFPM, MBA

• CEO & Managing Director• Actinogen Medical Limited

ANNE FAIRHALL

• Consumer Advocate• Alzheimer’s Australia Victoria

Actinogen Medical LimitedLevel 9, Suite 1, 68 Pitt Street, Sydney, NSW 2000 Australia

Dr. Bill Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years experience in the industry, including senior medical and management roles with global pharmaceutical giant, Pfizer. Prior to joining Actinogen

Medical, Dr. Ketelbey was Regional Vice President of Medical Affairs for Pfizer’s Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand. Dr. Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. At Pfizer, Dr. Ketelbey led the Australian/New Zealand clinical development, and was involved in the launch and commercialisation of Aricept™ (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer’s disease therapy locally and globally. More recently, he was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer’s. Dr. Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa, a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom, has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.

T: +61 2 8964 7401F: +61 2 8964 7588

E: bill.ketelbey@actinogen.com.au

Contact Details

M: +61 407 338 220E: fairhall@worksmart.com.au

Before rearranging her life to become her husband’s full time Home Carer, Anne served on many boards and committees, was

Managing Director of her own Management Consulting business, and had been a Senior Corporate Executive with National responsibilities. She originally trained as a Registered Nurse and ran operating theatres, before becoming an early adopter of Strategic Occupational Health and Safety Management. Her husband developed younger onset Frontal Temporal Lobe Dementia some 25 years ago, at age 51, and is now in residential care at age 77. She deliberately advocates widely for people impacted by dementia, promoting the need for cultural and systemic change in how we understand and support people living with dementia, their families and carers, as well as the ageing population more broadly. Anne is a regular guest speaker, media commentator, member of the Victorian Department of Health and Human Services – Public Sector Residential Aged Care Reference Group, and consults with Carers Australia Vic., National Ageing Research Institute and Blocks Global (Lumen Home). Anne is an honorary member of the Alzheimer’s Australia Victorian and National Consumer Advisory Network Groups, and has recently won a seniors award!

3111, 299 Queen StreetMelbourne, VIC 3000 Australia

www.actinogen.com.au 7

Speaker Associated Links & News

The Florey Institute & The University of Melbourne

McCusker Alzheimer’s Research Foundation

Alzheimer’s Australia Victoria

Home Page: www.florey.edu.au

MARF Home Page: https://alzheimers.com.au

Help sheets: https://www.fightdementia.org.au/about-dementia/resources/help-sheets

Dementia Awareness Month: https://vic.fightdementia.org.au/vic/dementia-awareness-month-2016

Virtual Dementia Experience: https://vic.fightdementia.org.au/vic/about-us/virtual-dementia-experience

Other Useful Websites:www.helpwithdementia.org.auwww.livingwellwithdementia.org.auwww.dementiainmyfamily.org.au

Profile for Professor Ralph Martins: http://www.ecu.edu.au/schools/medical-and-health-sciences/staff/profiles/professors/professor-ralph-martins-ao

Actinogen Medical Highlights

Investor Update Newsletter

Actinogen Medical has recently published its fifth volume of the Investor Update Newsletter series. To view it on our website, please visit the following link: http://bit.ly/InvestorUpdate

R&D Tax Rebate

Actinogen Medical is pleased to advise that the company has received a Research & Development Tax Incentive rebate of $2,784,312 for the 2015/2016 financial year. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 45% of eligible expenditure on research and development. To view the full announcement, please visit the following link: http://bit.ly/ACWrebate

Landmark Research

ASX Announcement:http://bit.ly/Cortisol-and-Alzheimers

Annual Report

Actinogen Medical has recently released its Annual Report of company operations. Please visit the following link to view the document in full: http://bit.ly/AnnualReportACW

http://bit.ly/XanamemPoster http://bit.ly/AIBLposter